Record Nr. UNINA9910787308103321 Maximizing the impact of the Cures Acceleration Network: accelerating **Titolo** the development of new drugs and diagnostics: workshop summary // Steve Olson and Anne B. Claiborne, rapporteurs; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies Washington, District of Columbia:,: National Academies Press,, Pubbl/distr/stampa [2012] ©2012 **ISBN** 0-309-26119-8 0-309-26117-1 Descrizione fisica 1 online resource (132 p.) Disciplina 615.1/9 Soggetti Drug monitoring Drug development - United States Drugs - United States - Design Pharmaceutical industry - United States - Quality control Lingua di pubblicazione Inglese **Formato** Materiale a stampa Livello bibliografico Monografia Note generali Description based upon print version of record. Nota di bibliografia Includes bibliographical references (pages 71). Nota di contenuto Introduction [The history and goals of CAN (Cures Acceleration Network)] -- Approaches to accelerating translational science --Application of matching authority -- Application of flexible research authority -- Situating CAN within the drug development ecosystem --Final reflections on ways to maximize the goals of CAN. Advances in technologies and knowledge are creating new avenues for Sommario/riassunto research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and

industry, all directed at the advancement of the drug development enterprise. The newly developed Cures Acceleration Network (CAN)-a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH)-has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. On June 4-5, 2012, the IOM Forum on Drug Discovery, Development, and Translation held, at the request of NCATS, a workshop-bringing together members of federal government agencies, the private sector, academia, and advocacy groups-to explore options and opportunities in the implementation of CAN. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary summarizes the workshop."--Publisher's description.